Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (March 2023)
41 slides from Perspective Therapeutics's investor presentation, Mar 15, 2023
Slide 1: Corporate Presentation
PERSPECTIVE THERAPEUTICS Corporate Presentation
Slide 2: Legal Disclaimers
Legal Disclaimers ‘Statements in this presentation about Perspective Therapeutics, Inc's (the “Company”) future expectations, including the functionality. capabilites, and benefits ofthe ‘Company's therapies including its targeted alpha particle radietherapy. whether favorable results ofthe intial t
Slide 3: Perspective Therapeutics
Perspective Therapeutics combined fo n jon cancer treatments using target delivery of radiation and imaging technologies. treating cancer from the inside out February3, 2023 completed merger with Isoray Medical + Commercially available Cs-131 for LOR brachytherapy ‘+ Multt.ndications for brachythera
Slide 4: Management Team
Management Team Deep Radiotherapy and Development Experience Thijs Spoor Markus Publmann, MD MBA Chief Medical Officer Jonathan Hunt Chie Financial Officer ‘Michael Schultz, PhD Co-Founder and Chief Scienc ‘Amos Hedt Chief B ess Strat PERSPECTIVE THERAPEUTICS
Slide 5: Targeting Cancer Cells from the inside out
Slide 6: Radiopharmaceuticals Are a New Pillar of Oncology Treatment with Pan-Cancer Opportunities
Radiopharmaceuticals Are a New Pillar of Oncology Treatment with Pan-Cancer Opportunities Pi Radiotherapy's a proven pillar of cancer treatment but lacks precision. By precisely delivering radiation Ges MMaetenid directly to cancer cells with radioligand, the power of radiotherapy can be realized wh
Slide 7: Targeted a-Particle Radiotherapy
Targeted a-Particle Radiotherapy A New Class of Oncology Therapeutics
Slide 8: Alpha Particles Have Superior Tumor Killing Properties vs. Beta-Particles
@Particles Have Superior Tumor Killing Properties vs. 6-Particles More Powerful Effects Than ‘Approved B. Therapy Higher atomic mass Lethal double-stranded DNA breaks DNA repair mechanisms overwhelmed Precision Delve PRM e005 creny over 29 cel dameters Targeted cen [ian beta particles (up to 200 cel
Slide 9: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (?4?Pb): The Optimal Therapeutic Isotope ‘Superior* Therapeutic Energy Expected to Improve Outcome with Better Safety Lutetium @77Lu) Implication* Emission Profile Beta Beta Aipha Alpha Potent Half Life 8 days 67 days 10 days. 0.46 days Rapid Clearance Off TargetToxicityRisk Very high Low H
Slide 10: Peptides emerging as ideal ligands for radiopharmaceutical therapy
Peptides emerging as ideal ligands for radiopharmaceutical therapy Peptides mAbs salen Le aaa | Sect velo +++ atity High (eM) ale ae ale | ny High (oM70M) a a ae Selectivity High BR | seoctwin’ High +++ Tumor specify Fost(Tyzhoun) aff affe af | Tumorspecitcy Slow (yzda7)——affakidney, ther other Clea
Slide 11: Ideal Theranostic 203Pb & Viewpoint Chelator
Ideal Theranostic 22Pb & Viewpoint Chelator + Ideal agreement between imagingand therapeutic + °°Pb and !2Pb matched pair compounds + Generator produced Readily available isotope + PSC carries O net charge + Ideal chelator + Peptide targeting + Rapid clearance from blood + High binding Low hospital
Slide 12: Theranostics: Understand Which Patients Will Respond to Therapy
Theranostics: Understand Which Patients Will Respond to Therapy 24 hours P useful in early BA raciopnarmaceutical eomontaly dential EY imaging surrogate | isp inert agent to establish ° Pb agent PK Twa 52h Dosimetry 203Ph Selection 212Ph Matches Peptide PK Linker Linker Imaging (See i) Targeting, Ca
Slide 13: Discovery Platform Gives Broad Proprietary Pipeline
Discovery Platform Gives Broad Proprietary Pipeline Progam Indication Neuroendocrine 13) Pheochromocytomas. paragangior 3s VMTaNET ‘Small cell lung cancer — MOL Melanoma (MC1R) \VMI-02 (PETagent) Melanoma Program A(Novel peptide) Multiple solid tumors Program B (Novel peptide) Prostate Program C(Nov
Slide 14: Neuroendocrine Tumors: VMT-a-NET
Neuroendocrine Tumors: VMT- Using the somatostatin receptor to type cancers
Slide 15: VMT-a-NET
VMT-a@-NET CO) Targeting somatostatin receptor type 2 (SSTR2) Currently in Phase 1/2a studies for the imaging and treatment of Initiated first-in-human imaging (2021) & therapy (2022) under neuroendocrine tumors ‘compassionate use US Phase | imaging study enrollingat the University of lowa. Therapeu
Slide 16: Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Malignancies of neuroendocrine cells, which are specialized cells that secrete hormones and other bioactive substances which are found throughout the body Often grows in the pancreas or other areas of the gut, such as the stomach, small intesti
Slide 17: CT SPECT Scan Hours After Injection
CT SPECT Scan ~ 24 Hours After Injection K ya 203Pb-DOTATOC 203Pb-VMT-a-NET Warm dicate greater retention of drug in tumor (T) Faint retention in kidney (K) PERSPECTIVE THERAPEUTICS
Slide 18: Imaging Reveals Favorable VMT-a-NET Properties
Imaging Reveals Favorable VMT-a-NET Properties Rapid Tumor Targeting andRenal Ha = 15 hrs SPECT/CT We + yz , 3 zane ‘SPECT/CT core oo 7 ¥ Rapid renal clearance ¥ Excellent tumor retention U unveum Whole body planar SPECT/CT PERSPECTIVE THERAPEUTICS
Slide 19: Imaging VMT-a-NET Clearly Identifies Lesions
Imaging VMT-a-NET Clearly Identifies Lesions [Pb-203 Vita NET Peptide ‘Ge-68 DOTANOE Clear uptake of tracert sites with hepatic metastases ¥ Whole body Planar (A) and transverse SPECT CT (B) images ac at 2 hours post injection of 2°°Pb-VMT- o-NET showed excellent uptake of Pb-203 VMT-a-NET peptide i
Slide 20: Preclinical Data
Preclinical Data ff orpAeninstres Lu]DOTATATE (3 x 500 Ci) vere = i i . _ _ .o— ma + Animal study in mice showing tumor growth curves of implanted neuroendocrine tumors + Mice were treated with placebo vs. an FDA approved beta-emitter + Targeted radiation shows improvements over placebo PERSPECTIVE
Slide 21: Preclinical Data
Preclinical Data VMT-a-NET shows improvements with single or multiple doses [177Lu]DOTATATE (3 x 500 Ci) coy PPOTATATED 90,0) ; as posto Ppp] (EA ETEED HCI) [2!2Pb] VMT-o-NET (4X30 Ci) PERSPECTIVE tomiaiiaman «= (a) PERsPee
Slide 22: Phase I/IIa Trial Design for VMT-a-NET
Phase I/lla Trial Design for [?72Pb]VMT-a-NET + Unresectable or metastatic SSTR2-positive neuroendocrine tumors + PRRT naive Population + Selection by approved SSTR2 PET/CT mTPlescalation Potential additional Dose escalation Dose expansion expansion up to N= 100 (2!2Pb] VMT-a-NET [22Pb] VMT-c-NET (2
Slide 23: Clinical Development Plan VMT-a-NET
Clinical Development Plan VMT-a@-NET Data expected 2023 All neuroendocrine tumor types ‘Compassionate Image- Guided Therapy Phase I/Ila Dose Escalation Study Clinical Sites: Multiple global sites, Clinical Site: Multiple in US; Mayo, Ul and UW + ‘Subjects: Up to 7 with refractory NETS ‘Subjects: ~30
Slide 24: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor MC1R to target melanoma for imaging and therapy
Slide 25: VMT01/02
VMTO01/02 CO) Targeting melanocortin 1 receptor (MC1R) Currently in Phase 1/2a studies for the imaging Preclinical combination data (published) resulted in $2m NIH SBIR Grant andtreatment of metastatic melanoma Provisional results from completed Phase 1 imaging study expected H1 2023 Studies being c
Slide 26: Metastatic Melanoma
Metastatic Melanoma Advanced stages of disease occurs throughout the body Brain requiring aggressive systemic treatment Lymph nodes Significant unmet need withan Lungs $8 billion market opportunity ~100K new diagnoses of ‘Skin (Primary) a ‘melanoma annually? ~6,850 deaths annually from metastatic me
Slide 27: Whole body planar SPECT/CT
Whole body planar SPECT/CT PERSPECTIVE THERAPEUTICS
Slide 28: Demonstrated Complete Responses VMT01/02 in Multiple Animal Tumor Models
Demonstrated Complete Responses VMT01/02 in Multiple Animal Tumor Models Single dose of VMTO1 significantly arrested Key Takeaways + High response rates in multiple tested 100: Immuredetient human ‘melanomaxengaft model models Be ae + 43% complete and durable response 30 Sing done VuTO1 + BEE if com
Slide 29: Clinical Development Plan VMT01
Clinical Development Plan VMTO1 Data expected in 2023 Metastatic Melanoma Completed Phase 1 Imaging Study Phase I/Ila Dose Escalation Study Clinical Site: Mayo Clinic (Rochester, MN) Clinical Site: 5 US sites +/- expansion to 15 ‘Subjects: 7: Stage III/IV unresectable melanoma ‘Subjects: ~30; Stage
Slide 30: Supporting Program: VMT-a-GEN
Supporting Program: VMT-a-GEN Controlling the Therapeutic Isotope
Slide 31: VMT-a-GEN
VMT-2-GEN + “Limitless” feedstock from nuclear and mining waste material + Long:term supply contract secured (US DOE) + On demand daily doses + Auto-regenerates overnight + ~1. week shelf life | | 35 Small, Elegant 2!2Pb Isotope Generator * Integrated lead shielded containment + Simple inlet and out
Slide 32: Controlling the Therapeutic Isotope Supply
Controlling the Therapeutic Isotope Supply Raw Materials Manufacturing Distribution AK RIDGE ional Laboratory 228Th Feedstock DOE Supply 22Pb generator loading, shipping Manufacturing of Cold Kits PERSPECTIVE THERAPEUTICS
Slide 33: Corporate Overview
Corporate Overview
Slide 34: Intellectual Property
Intellectual Property Fully Licensed University IP VV) 3 provisional patents + Composition of Matter and Use VMT-o-NET, Chelator + USA, EU, Australia issued patents + Composition of matter and use on melanoma targeting peptides + USA + Composition of Matter and Use VMTO1 + USA, EU, Australia Potenti
Slide 35: Clinical Trial Principal Investigators
Clinical Trial Principal Investigators Renowned Experts in Radiotherapy Development Geoffrey B. Johnson MD, PhD Chair, Division of Nuclear Medicine Chair, PET/MR R&D ProtessorofRedo IOWA Chair, Division of Nuclear Medicine ‘Associate Professor Departments of Radiology and Project Leader Immunology M
Slide 36: Slide 36
Slide 37: Appendices
Appendices
Slide 38: Isotope: Decay chain — Biological implications
Isotope: Decay chain — Biological implications 22®Ac Decay Series =) a Alpha-particle emission imparts sufficient “recoil” energy to break chemical bonds. OH
Slide 39: Isotope: Decay chain — Product implications
Isotope: Decay chain — Product implications Post final radiolabeling and purification, alpha and beta emitting daughters of 22°Ac build up fast. 15 Decay and Daughter ingrowth Radioactivity (Bq) 6000 5000 4000 3000 2000 1000 ° mAC225 mFr221 mAL2IT mBi213 = T1209 mPo-213 ieee absaveuts cease ° i 2 3
Slide 40: Isotope: Decay chain and chelator selection
Isotope: Decay chain and chelator selection 22Pb Decay Series ‘ae Parent Material y “R28 | 24Ral?"2Pb Generator (2Pp|Psc A PERSPECTIVE THERAPEUTICS
Slide 41: Slide 41
Perspective Therapeutics — Investor Presentation (March 2023) on 6ix